USC scientists find way to create renewable supply of cancer-fighting immune cells

USC researchers developed a platform using granulocyte-monocyte progenitors (GMPs) that can be expanded extensively in the lab and genetically engineered to recognize tumors. In mice, the engineered cells engrafted in bone marrow and slowed blood cancers and solid tumors. The study was published in Cell.

• GMP progenitors multiply in the lab while retaining the ability to become immune cells
• In mice, engineered cells engrafted in bone marrow and slowed tumor growth
• The approach could address manufacturing limits of cell immunotherapy
• The study was published in the journal Cell